|Awarded On||February 15, 2023|
|Title||Rational design, synthesis and biological evaluation of simplified taccalonolide analogs for the treatment of cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas at San Antonio|
|Principal Investigator/Program Director||Douglas Frantz|
|Cancer Sites||All Sites|
*Pending contract negotiation
Naturally occurring compounds have historically provided a rich source of successful drug treatments for cancer. In fact, several of Nature's chemical harvests have been directly developed into life-saving chemotherapies without chemical modification such as paclitaxel that is recognized on the World Health Organization's (WHO) list of essential medicines. However, the direct preclinical development of most natural products, even those with promising anti-cancer activities, remains a formidable challenge due to significant hurdles that impede the drug discovery process. Most significant of these hurdles is the lack of early drug supplies due to low natural abundance or complex chemical struc...